Calls for papers
-
Acorda Therapeutics has announced that clinical trials of Plumiaz diazepam nasal spray have failed to demonstrate bioequivalence to Diastat rectal gel, which means that the company is unable to re-file its 505(b)(2) NDA for the… Read more . . .
-
A study published in the journal Nicotine and Tobacco Research found that 32% of smokers using a nicotine MDI plus a nicotine patch quit for 6 months compared to 18% of smokers using a placebo… Read more . . .
-
Generic inhalation device developer Merxin has announced the launch of its MRX002 clear PET pMDI can, which allows developers to observe and model formulations in laboratory settings. According to the company, the cans are compatible… Read more . . .
-
Avanir Pharmaceuticals has announced the launch of Onzetra Xsail sumatriptan nasal powder in the US. The FDA approved Onzetra Xsail for the treatment of migraine in adult patients in January 2016. In 2013, Avanir acquired… Read more . . .
-
US biotechnology company NeOnc Technologies has announced the initiation of a Phase 1/2a clinical trial of NEO100 intranasal perillyl alcohol (POH) for the treatment of glioblastoma multiforme (GBM), an aggressive brain cancer. Five-year survival for… Read more . . .
-
An online survey of 205 pulmonologists and pulmonology fellows conducted by the American Thoracic Society and Sunovion Pharmaceuticals has found that two thirds of the physicians believe that hand-held nebulizers are superior to both MDIs… Read more . . .
-
The US Department of Health and Human Services (HHS) has announced that its Biomedical Advanced Research and Development Authority (BARDA) has issued a $10.49 million task order to the Centers for Innovation in Advanced Development… Read more . . .
-
CRO Aptuit has acquired preclinical formulation specialist Kuecept Ltd, the company said. Both companies have extensive experience in respiratory drug delivery. Kuecept Founder and CEO Mark Saunders commented, “Since our inception in 2007, we have… Read more . . .
-
Grupo Ferrer will acquire inhaled drug developer Alexza Pharmaceuticals for $0.90 per share in a deal that is expected to be completed by mid-2016, the two companies have announced. In February 2016, Alexza announced that… Read more . . .
-
Submission for podium and poster presentations are due by July 29, 2016. Areas of particular interest for DDL27 include: • Inhalers – were they really meant for humans? • Beyond Asthma and COPD • 60… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK